This Program Guide PDF was released to press on March 15, 2016. Please note that some sessions and presentations have changed since that time. The current Annual Meeting program is available electronically in the following formats:

- Online Itinerary Planner
- Annual Meeting App (for iOS and Android devices)

Please refer to the electronic versions of the program for the most up-to-date information.
MEET-THE-EXPERT SESSIONS • 7:00 a.m.–8:00 a.m.

Room 291, Morial Convention Center
Bringing Longitudinal Research and Clinical Data Together to Accelerate Translation
Andy Futreal, Houston, TX

Room 288, Morial Convention Center
Cellular Plasticity, Cellular Heterogeneity, and Single Cell Sequencing
Xin Lu, Oxford, United Kingdom

Room 265, Morial Convention Center
Epigenetic Therapies: From Bench to Bedside in Acute Myeloid Leukemia
Mark Dawson, Melbourne, Australia

Room 388, Morial Convention Center
Identifying Driver Genes in Melanoma
Yardena Samuels, Rehovot, Israel

Room 254, Morial Convention Center
Linking Genes, Environment, and Cancer: Lessons from the Mouse
Allan Balmain, San Francisco, CA

Room 243, Morial Convention Center
Liquid Biopsies: Monitoring the Cancer Genome in Blood
Sarah-Jane Dawson, Melbourne, Australia

Room 354, Morial Convention Center
Making the Most of Single Cell RNA-Seq Data
Dana Pe’er, New York, NY

Room 275, Morial Convention Center
Molecular Pathology 101
How to Optimize and Validate Immunohistochemical and In Situ Hybridization Assays: Pitfalls, Pearls, and Power
Angelo M. De Marzo, Baltimore, MD

Room 260, Morial Convention Center
Monitoring Humoral and Cellular Immune Responses from Blood and Tumor in Cancer Immunotherapy
Sacha Gnjatic, New York, NY
Room 357, Morial Convention Center
**Stapled Peptides as a New Form of Medicine for Oncology Targets: Challenges and Progress**
David P. Lane, Singapore, Singapore

Room 383, Morial Convention Center
**Targeting EZH2: Understanding the Function of Polycomb Group Proteins**
Kristian Helin, Copenhagen, Denmark

Room 391, Morial Convention Center
**The Evolution of Tumors in Mice and Humans with Inherited p53 Mutations**
Arnold J. Levine, Princeton, NJ

Room 271, Morial Convention Center
**The Role of Metabolism in Supporting Tumor Growth**
Matthew G. Vander Heiden, Cambridge, MA

Room 343, Morial Convention Center
**Topic to Be Announced**
George Coukos, Lausanne, Switzerland

▲**NCI/NIH-SPONSORED SESSION • 7:00 a.m.–8:00 a.m.**

Room 352, Morial Convention Center
**NIH Grants Session: Changes in Review, Funding, and Funding Opportunities at the NCI**
(not eligible for CME credit)

**Chairperson:** Daniel L. Gallahan, Bethesda, MD

**Speakers:** Daniel L. Gallahan, Bethesda, MD
Nywana Sizemore, Bethesda, MD
Join us on Sunday for the Annual Meeting Opening Ceremony, a yearly tradition marking the start of four days filled with outstanding and innovative science.

AACR CEO Margaret Foti will address attendees and discuss the tremendous progress the AACR has made over the past year.

AACR President José Baselga will highlight the dramatic advances in cancer research and today’s challenges in the cancer field.

The Opening Ceremony will also feature the presentation of some of the AACR’s most prestigious awards, including:

- The Tenth Annual AACR Team Science Award
- The NextGen Grants for Transformative Cancer Research
- The Thirteenth Annual AACR Award for Lifetime Achievement in Cancer Research
- Recognition of the newly inducted Fellows of the AACR Academy
- The Tenth Annual AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
- The Inaugural AACR June L. Biedler Prize for Cancer Journalism
- The 2016 AACR Distinguished Public Service Awards

Don't miss this exciting event, which leads directly into the Opening Plenary Session!
PLENARY SESSION • 9:30 a.m.–12:00 p.m.

Hall F, Morial Convention Center

Opening Plenary

**Breakthroughs in Cancer Research: Genomics, Epigenetics, and Immunomodulation**

**Chairperson:** Scott A. Armstrong, New York, NY

**9:30 a.m.**  
*Cancer genomics: A translational future.*  
Elaine R. Mardis, St. Louis, MO

**10:00 a.m.**  
*Targeting epigenomic dependencies in cancer.*  
James E. Bradner, Cambridge, MA

**10:30 a.m.**  
*Genome editing using CRISPR-Cas systems.*  
Feng Zhang, Cambridge, MA

**11:00 a.m.**  
*T cell recognition of human cancer.*  
Ton Schumacher, Amsterdam, The Netherlands

**11:30 a.m.**  
*Stem cells and cancer.*  
Elaine Fuchs, New York, NY

---

SCIENCE POLICY SESSION • 11:00 a.m.–12:30 p.m.

Room 352, Morial Convention Center

**The Impact of the Affordable Care Act (ACA) on Cancer Research, Care, and Prevention**

**Chair and Moderator:** Gilbert S. Omenn, Ann Arbor, MI

**Speakers:**  
William S. Dalton, Tampa, FL  
Mary J. Scroggins, Washington, DC  
Ernest T. Hawk, Houston, TX  
Jennifer Singleterry, Washington, DC

---

PRESIDENTIAL ADDRESS • 1:00 p.m.–2:00 p.m.

Hall F, Morial Convention Center

José Baselga, New York, NY
SUNDAY, APRIL 17

▲ MEET AND GREET • 1:00 p.m.–2:00 p.m.

AACR Publications Booth (2030), Exhibit Halls G-J
Meet the Editor-in-Chief of Clinical Cancer Research
(not eligible for CME credit)
Kenneth C. Anderson, Boston, MA

▲ NCI/NIH-SPONSORED SESSION • 1:00 p.m.–2:00 p.m.

Room 352, Morial Convention Center
Funding Opportunities from the Recalcitrant Cancer Research Act of 2012
(not eligible for CME credit)
Pancreatic cancer initiatives. Sudhir Srivastava, Rockville, MD
SCLC: Coordinating center and approaches to diagnosis and prevention. Eva Szabo, Rockville, MD
Therapeutic development and mechanisms of resistance in SCLC. Suzanne Forry, Rockville, MD

▲ SCIENCE POLICY SESSION • 1:00 p.m.–2:30 p.m.

Room 334, Morial Convention Center
The Intersection of Science Policy and Cancer Research: A Town Hall Meeting on the Vice President’s Cancer Initiative and AACR’s Advocacy Efforts
(not eligible for CME credit)
Chair and Moderator: Roy A. Jensen, Kansas City, KS
Speakers: Jon G. Retzlaff, Washington, DC
Mary Lee Watts, Washington, DC
Lee D. Gibbs, Fort Worth, TX
Mary Jackson Scroggins, Washington, DC
PROFESSIONAL ADVANCEMENT SESSION • 1:00 p.m.–2:30 p.m.

Grand Salon B, Hilton New Orleans Riverside
Off the Bench: A Guide to Cancer Research Careers
Beyond the Traditional Academic Path
Organized by the Associate Member Council (AMC)
(not eligible for CME credit)
Forging a non-traditional career: Academia. David A. Fruman, Irvine, CA
Forging a non-traditional career: Industry. Susan M. Galbraith, Macclesfield, United Kingdom
Forging a non-traditional career: Government. Jean C. Zenklusen, Bethesda, MD
Forging a non-traditional career: Nonprofit. Pat J. Morin, Philadelphia, PA
Panel discussion Q&A
Networking session with invited guests

REGULATORY SCIENCE AND POLICY SESSION
1:00 p.m.–3:00 p.m.

Room 283, Morial Convention Center
A Discussion of Early-Phase Expansion Cohort Trial Design in the Development of Future Oncology Products
Chairperson: Tatiana Prowell, Silver Spring, MD
Speakers: Philippe L. Bedard, Toronto, ON, Canada
Roy Jones, Houston, TX
Samantha Roberts, Washington, DC
Eric Rubin, North Wales, PA (not eligible for CME credit)
Lillian L. Siu, Toronto, ON, Canada
AACR Annual Meeting 2016
Program Guide PDF

Poster Sessions:
Abstract Presentations

The complete titles and text of poster session abstracts are available in the following formats:

- Online Itinerary Planner
- Annual Meeting App (for iOS and Android devices)
Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner, the Annual Meeting App (available at www.AACR.org/AACR2016), and in the print Poster Sessions and Exhibits Guide. A limited number of copies of the print guide are available in the Exhibit Hall.

**Molecular and Cellular Biology/Genetics**

- Section 1  Altered Cellular Signaling and Cancer Metabolomics
- Section 2  Altered Glucose Metabolism in Cancer
- Section 3  Functional Genomics and Genomics of Model Systems
- Section 4  Genomic Analysis of Cancers
- Section 5  Genomic Profiling of Cancers
- Section 6  Intratumor Heterogeneity and Resistance
- Section 7  Kinases and Phosphatases
- Section 8  Mitochondria, Autophagy, and Metabolic Vulnerabilities
- Section 10 Late-Breaking Research: Molecular and Cellular Biology 1

**Cancer Chemistry**

- Section 12 Late-Breaking Research: Cancer Chemistry

**Experimental and Molecular Therapeutics**

- Section 14 Cellular Processes and Responses to Therapy
- Section 15 Combination Chemotherapy
- Section 16 Mechanisms of Drug Resistance 1
- Section 17 Novel Antitumor Agents
- Section 18 Novel Assays
- Section 19 PI3K/AKT Inhibitors

**Clinical Research**

- Section 20 Biomarkers
- Section 21 Biomarkers for Genitourinary and Gynecological Cancers
- Section 22 Biomarkers for Melanoma and Uncommon Cancers
- Section 23 Circulating Biomarkers 1
- Section 24 Radiation Oncology
**Immunology**

Section 25  Genetic Determinants and Regulators of Cancer Immunity
Section 26  Immune Modulating Agents 1
Section 27  Therapeutic Antibodies

**Tumor Biology**

Section 11  Late-Breaking Research: Tumor Biology 1
Section 28  Drug Testing in Cell Lines and 3D Models
Section 29  Human in Mouse Models
Section 30  Mechanisms of Tumorigenesis in Animal Models of Cancer 1
Section 31  Molecular Regulation of Tumor Invasion
Section 32  Pro-Tumorigenic Microenvironment
Section 33  Targeting the Microenvironment

**Bioinformatics and Systems Biology**

Section 34  Systems Biology

**Epidemiology**

Section 36  Genes and Function and Risk

**Prevention Research**

Section 37  Models and Mechanisms in Cancer Prevention

▲CAREER CONVERSATIONS • 1:15 p.m.–2:00 p.m.

AACRcentral, Associate Member Resource and Career Center

**Physician-scientists: Leveraging Your Training and Carving Out Your Niche**

*Organized by the Associate Member Council (AMC)*

(not eligible for CME credit)

**Speakers:** Gregory L. Beatty, Philadelphia, PA
   Eliezer M. Van Allen, Boston, MA
SUNDAY, APRIL 17

▲ SPECIAL SESSION • 1:15 p.m.–2:15 p.m.

AACRcentral Amphitheater

MEG Working Group Networking Event with Early-Career Researchers: The Role of Molecular Epidemiology in Precision Medicine
(not eligible for CME credit)

1:15 p.m.  Opening remarks: Co-moderators. Jonine D. Figueroa, Edinburgh, United Kingdom; Leah E. Mechanic, Bethesda, MD

1:20 p.m.  Speakers: Nilanjan Chatterjee, Rockville, MD
            Ulrike Peters, Seattle, WA
            Avrum E. Spira, Boston, MA

▲ MEET AND GREET • 1:30 p.m.–3:00 p.m.

AACRcentral, MICR Networking and Resource Center, Exhibit Halls G-J

MICR Council Meet and Greet
Organized by the Minorities in Cancer Research (MICR) Council
(not eligible for CME credit)

Chairperson: Edith A. Perez, South San Francisco, CA
Past Chairperson: Chanita Hughes-Halbert, Charleston, SC
Chairperson-Elect: Rick A. Kittles, Tucson, AZ
Chairperson-Elect Designate: John M. Carethers, Ann Arbor, MI
Council Members: Lisa L. Baumbach-Reardon, Phoenix, AZ
                Claudia R. Baquet, Columbia, MD
                Christopher S. Lathan, Boston, MA
                Lisa A. Newman, Detroit, MI
                Coleman K. Obasaju, Indianapolis, IN
                Brian M. Rivers, Atlanta, GA
                Sanya A. Springfield, Bethesda, MD
                John H. Stewart, Durham, NC
                Charles R. Thomas, Portland, OR
MEET AND GREET • 2:00 p.m.–4:00 p.m.

AACRcentral, WICR Networking and Resource Center, Exhibit Halls G-J

WICR Council Meet and Greet
Organized by the Women in Cancer Research (WICR) Council
(not eligible for CME credit)

Chairperson: Victoria M. Richon, Wellesley Hills, MA
Past Chairperson: Jessie M. English, Billerica, MA
Chairperson-Elect: Patricia M. LoRusso, New Haven, CT
Council Members: Lucile L. Adams-Campbell, Washington, DC
Caroline Dive, Manchester, United Kingdom
Lori S. Friedman, South San Francisco, CA
Pearl S. Huang, Basel, Switzerland
S. Percy Ivy, Rockville, MD
Kornelia Polyak, Boston, MA
Judith S. Sebolt-Leopold, Ann Arbor, MI
Lillian L. Siu, Toronto, ON, Canada
Thea D. Tlsty, San Francisco, CA

NCI/NIH-SPONSORED SESSION • 2:15 p.m.–3:45 p.m.

Room 352, Morial Convention Center

NCI’s Center for Cancer Genomics: Initiatives to Further Precision Medicine
(not eligible for CME credit)

Co-Chairpersons: Jaime M. Guidry Auvil, Bethesda, MD; Jean C. Zenklusen, Bethesda, MD

Overview of NCI Center for Cancer Genomics programmatic objectives. Jaime M. Guidry Auvil, Bethesda, MD

CCG precision medicine collaborations initiatives: ALCHEMIST and exceptional responders. Roy Tarnuzzer, Bethesda, MD

CTD² Network updates. Subhashini Jagu, Bethesda, MD

CCG tumor characterization initiatives: TARGET pediatric cancer genomics initiative and CGCI updates. Jaime M. Guidry Auvil, Bethesda, MD


Newer CCG initiatives: CDDP and CTSP. Jean C. Zenklusen, Bethesda, MD

Large-scale data storage and access for CCG initiatives: Genomic Data Commons. Tanja M. Davidsen, Bethesda, MD
MAJOR SYMPOSIA • 2:15 p.m.–4:00 p.m.

Room 288, Morial Convention Center

**Developmental Pathways**

**Chairperson:** Duojia D. J. Pan, Baltimore, MD

**2:15 p.m.** Introduction

**2:25 p.m.** Stem cells and signaling pathways in regeneration and malignancy. Philip A. Beachy, Stanford, CA

**2:55 p.m.** Targeting stem cell pathways in human cancer. Ruggero De Maria, Roma, Italy [SY01-02]*

**3:25 p.m.** The Hippo signaling pathway in organ size control and tumorigenesis. Duojia D. J. Pan, Baltimore, MD

New Orleans Theater A, Morial Convention Center

**Epigenetics and Signaling in Cancer**

**Chairperson:** Karen M. Cichowski, Boston, MA

**2:15 p.m.** Introduction

**2:25 p.m.** Convergence of signaling activation and epigenetic dysregulation in myeloid malignancies. Ross L. Levine, New York, NY

**2:55 p.m.** Co-targeting epigenetic regulators and oncogenic signaling pathways in cancer. Karen M. Cichowski, Boston, MA

**3:25 p.m.** Epigenetic and kinase crosstalk in solid tumors. Ramon E. Parsons, New York, NY

Room 293, Morial Convention Center

**Inflammation and Cancer: Targeting the Myeloid Microenvironment**

**Chairperson:** Lisa M. Coussens, Portland, OR

**2:15 p.m.** Introduction

**2:25 p.m.** Macrophage PI3Kgamma drives cancer immune suppression. Judith A. Varner, La Jolla, CA [SY03-01]*

**2:55 p.m.** Deciphering mechanisms of resistance to macrophage-targeted therapies. Johanna A. Joyce, Lusanne, Switzerland

**3:25 p.m.** Paracrine nexus of intratumoral leukocytes: Fueling response and resistance of immunotherapies. Lisa M. Coussens, Portland, OR

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
Room 265, Morial Convention Center
**Dharma Master Jiantai Symposium in Targeted Therapy: Mutant p53 Activities and Targeted Therapies**

**Chairperson:** Guillermina Lozano, Houston, TX

2:15 p.m. **Introduction**

2:25 p.m. **The in vivo gain-of-function activities of mutant p53.** Guillermina Lozano, Houston, TX [SY04-01]*

2:55 p.m. **Opposing roles of wild-type and mutant forms of p53.** Carol L. Prives, New York, NY

3:25 p.m. **Improving survival by exploiting tumor dependence on stabilized mutant p53 in mouse mode.** Ute Moll, Stony Brook, NY [SY04-03]*

New Orleans Theater B, Morial Convention Center
**Precision Checkpoint Immunotherapy**

**Chairperson:** Antoni Ribas, Los Angeles, CA

2:15 p.m. **Immune checkpoints limiting responses to cancer.** Gordon Freeman, Boston, MA

2:45 p.m. **Selectable markers for checkpoint inhibitor immunotherapy.** Janis M. Taube, Baltimore, MD

3:15 p.m. **Targeting adaptive immune resistance.** Antoni Ribas, Los Angeles, CA

Room 343, Morial Convention Center
**The Roles of Non-coding RNAs in Cancer**

**Chairperson:** Phillip A. Sharp, Cambridge, MA

2:15 p.m. **Introduction**

2:25 p.m. **IncRNA networks.** Lynne Maquat, Rochester, NY

2:55 p.m. **The LIN28/let-7 pathway in development and disease.** George Q. Daley, Boston, MA

3:25 p.m. **Regulatory RNAs.** Nikolaus Rajewsky, Berlin, Germany

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings* (the abstract number is listed in brackets above).
Room 357, Morial Convention Center

**The Science of Surviving: Looking Back to Inform the Future**

**Chairperson:** Smita Bhatia, Birmingham, AL

*2:15 p.m.* Introduction

*2:25 p.m.* Childhood cancer survivorship research: Has it informed clinical practice? Leslie L. Robison, Memphis, TN

*2:55 p.m.* What have we learned from survivors of adult-onset cancer? Lois B. Travis, Indianapolis, IN

*3:25 p.m.* Personalizing treatment to reduce long-term morbidity: Are we there yet? Smita Bhatia, Birmingham, AL

Room 393, Morial Convention Center

**AACR-Bayard D. Clarkson Symposium: Tumor Cell of Origin and Cancer Stem Cells**

**Chairperson:** Luis F. Parada, New York, NY

*2:15 p.m.* Introduction

*2:25 p.m.* Cell of origin role in cancer stem cell and GBM phenotype. Luis F. Parada, New York, NY

*2:55 p.m.* Normal and neoplastic stem cells. Irving L. Weissman, Stanford, CA [SY08-02]*

*3:25 p.m.* Lgr5+ stem cells in self-renewal and disease of the stomach. Nicholas Barker, Singapore, Singapore

**RECENT ADVANCES IN DIAGNOSTICS AND THERAPEUTICS RESEARCH • 2:15 p.m.–4:00 p.m.**

Room 243, Morial Convention Center

**Hormone Receptors and Breast Cancer**

**Chairperson:** Sarat Chandarlapaty, New York, NY

*2:15 p.m.* Mutational landscape of hormone independent breast cancer. Sarat Chandarlapaty, New York, NY

*2:45 p.m.* Activation and crosstalk among nuclear receptors in breast cancer. Suzanne D. Conzen, Chicago, IL

*3:15 p.m.* Epigenetics of hormone receptor action in breast cancer. Mathieu Lupien, Toronto, ON, Canada

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
RECENT ADVANCES IN ORGAN SITE RESEARCH
2:15 p.m.–4:00 p.m.

Room 291, Morial Convention Center
Multiple Myeloma
Chairperson: Kenneth C. Anderson, Boston, MA

2:15 p.m. The impact of genomics on diagnosis, prognosis, and treatment of myeloma. Faith E. Davies, Little Rock, AR

2:45 p.m. The importance of plasma cell biology in treating newly diagnosed multiple myeloma. Sagar Lonial, Atlanta, GA

3:15 p.m. Treatment of relapsed myeloma with novel targeted and immune therapies. Kenneth C. Anderson, Boston, MA

Room 275, Morial Convention Center
New Actionable Targets in Malignancies of the Upper Aerodigestive Tract
Chairperson: Lillian L. Siu, Toronto, ON, Canada

2:15 p.m. Whole exome sequencing study of nasopharyngeal and esophageal cancers. H. Phillip Koeffler, Los Angeles, CA

2:45 p.m. Comprehensive molecular profiling datasets in head and neck squamous cell cancer. Jennifer Rubin Grandis, San Francisco, CA

3:15 p.m. What are actionable targets in the management of head and neck squamous cell and nasopharyngeal cancers? Brigette B. Ma, Hong Kong, Hong Kong

Room 260, Morial Convention Center
The Treatment of Advanced Soft Tissue Sarcoma and Gastrointestinal Stromal Tumors
Chairperson: Patrick Schöffski, Leuven, Belgium

2:15 p.m. Introduction. Patrick Schöffski, Leuven, Belgium

2:20 p.m. Emerging first line systemic treatment options for advanced soft tissue sarcoma. William Tap, New York, NY

2:40 p.m. New evidence-based treatment standards for advanced inoperable leiomyo- and liposarcomas after failure of first-line chemotherapy. Patrick Schöffski, Leuven, Belgium

3:00 p.m. Experimental treatment options for gastrointestinal stromal tumors with primary or secondary resistance to tyrosine kinase inhibitors. Suzanne George, Boston, MA

3:20 p.m. Clinical genomic testing in sarcoma for risk stratification, treatment selection, and disease monitoring. Marc Ladanyi, New York, NY
RECENT ADVANCES IN PREVENTION RESEARCH
2:15 p.m.–4:00 p.m.

Room 271, Morial Convention Center

**Global Cancer Prevention**

**Chairperson:** Rengaswamy Sankaranarayanan, Lyon, France

**2:15 p.m.**  
Global experiences in implementing cancer prevention interventions in low- and middle-income countries (LMICs). Rengaswamy Sankaranarayanan, Lyon, France

**2:45 p.m.**  
Innovative approaches to prevent and treat cervical cancer globally. Kathleen Schmeler, Houston, TX

**3:15 p.m.**  
Esophageal cancer prevention in China. You-lin Qiao, Beijing, China

**DRUG DEVELOPMENT TRACK: SPECIAL SESSION**
2:15 p.m.–4:15 p.m.

New Orleans Theater C, Morial Convention Center

**New Drugs on the Horizon 1**

**Co-Chairpersons:** Lori S. Friedman, South San Francisco, CA; Indrawan J. Mcalpine, San Diego, CA

**2:15 p.m.**  
Discovery and pre-clinical pharmacology of AZD0156: A first-in-class potent and selective inhibitor of Ataxia telangiectasia mutated (ATM) kinase. Elaine Cadogan, Cambridge, United Kingdom

**2:39 p.m.**  
A selective CDC7 inhibitor (LY3177833) impacts chromosome dynamics and has robust and durable activity in PDX tumor models. Xiang S. Ye, Shanghai, China

**3:03 p.m.**  
JNJ-61610588: A human anti-VISTA antibody induces antitumor responses via a unique mechanism of action. Linda A. Snyder, Spring House, PA (not eligible for CME credit)

**3:27 p.m.**  
MBG453: A high affinity, ligand-blocking anti-TIM-3 monoclonal Ab. Catherine A. Sabatos-Peyton, Cambridge, MA (not eligible for CME credit)

**3:51 p.m.**  
First-in-class T cell-redirecting bispecific antibody targeting glypican-3: A highly tumor-selective antigen. Takahiro Ishiguro, Tokyo, Japan [DDT01-05]*

*An extended abstract for this presentation is available in the Invited Abstracts section of the Proceedings (the abstract number is listed in brackets above).
**CLINICAL TRIALS PLENARY SESSION 1 • 2:15 p.m.-4:15 p.m.**

La Nouvelle Ballroom, Morial Convention Center

**Immuno-oncology Clinical Trials I**

Chairperson and discussants to be announced

CT002  **Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL).** Michael Postow, New York, NY

CT003  **A phase I study of an HLA-DPB1*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer.** Yong-Chen Lu, Bethesda, MD

CT004  **KEYNOTE-006: PD-L1 expression and efficacy in patients (pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma.** Matteo Carlino, Wentworthville, Australia

CT001  **Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial.** F. Stephen Hodi, Boston, MA

**CAREER CONVERSATIONS • 2:30 p.m.–3:30 p.m.**

AACRcentral, Associate Member Resource and Career Center

**Searching for the Right Postdoctoral Position**

*Organized by the Associate Member Council (AMC)*

(not eligible for CME credit)

**Speakers:** Paul A. Northcott, Memphis, TN
Clodia Osipo, Maywood, IL

**MEET THE RESEARCH ICON • 2:30 p.m.–3:30 p.m.**

AACRcentral Amphitheater

**Meet the Pancreatic Cancer Research Icon: Frank McCormick**

(not eligible for CME credit)

Frank McCormick, San Francisco, CA
SCIENCE POLICY SESSION • 3:00 p.m.–4:30 p.m.

Room 283, Morial Convention Center
Tobacco Control Policy Session
The Need for ENDS Regulations: Public Health Concerns and Opportunities

Chair and Moderator: Roy S. Herbst, New Haven, CT

Speakers: Peter G. Shields, Columbus, OH
          Brian A. King, Atlanta, GA
          Lauren Dutra, San Francisco, CA
          Ray Niaura, Washington, DC

MEET AND GREET • 3:45 p.m.–4:45 p.m.

AACRcentral Amphitheater
Meet the Mentor I: Undergraduate Focus Featuring Danny R. Welch
(not eligible for CME credit)

Chairperson: Kathleen W. Scotto, New Brunswick, NJ
Mentor: Danny R. Welch, Kansas City, KS

MEET THE RESEARCH ICON • 3:45 p.m.–4:45 p.m.

AACRcentral, Associate Member Resource and Career Center
Meet the Research Icon: Joan S. Brugge
Organized by the Associate Member Council (AMC)
(not eligible for CME credit)

Joan S. Brugge, Boston, MA
NCI/NIH-SPONSORED SESSION • 3:45 p.m.–5:15 p.m.

Room 352, Morial Convention Center

**NCI’s Cancer Genomics Cloud Pilots**
*(not eligible for CME credit)*

**Chairperson:** Anthony Kerlavage, Rockville, MD

**Overview of NCI Genomics Data Commons and Cancer Genomics Cloud Pilots.**
Ishwar Chandramoulswaran, Bethesda, MD

**Specific Cancer Genomics Cloud Pilot initiatives.**
- Brandi Davis Dusenbery, Cambridge, MA
- Ilya Shmulevich, Seattle, WA
- Gad Getz, Charlestown, MA

**Cancer Genomics Cloud Pilot user talks:**
- **Resolving tumor heterogeneity using the Cancer Genomics Cloud.** Jeffrey H. Chuang, Farmington, CT
- **Cloud-enabled parallel variant calling and data sharing in PanCanAtlas.** Kuan-lin Huang, St. Louis, MO
- **Using Firecloud for rapid tumor heterogeneity analysis.** Ignaty Leshchiner, Cambridge, MA

**CGC Roundtable**

**Panelists:**
- Anthony Kerlavage, Rockville, MD
- Ishwar Chandramoulswaran, Bethesda, MD
- Brandi Davis Dusenbery, Cambridge, MA
- Ilya Shmulevich, Seattle, WA
- Gad Getz, Charlestown, MA
- Jeffrey H. Chuang, Farmington, CT
- Kuan-lin Huang, St. Louis, MO
- Ignaty Leshchiner, Cambridge, MA

Room 254, Morial Convention Center

**The NCI RAS Initiative at the Frederick National Laboratory for Cancer Research**
*(not eligible for CME credit)*

**Speakers:**
- Frank McCormick, San Francisco, CA
- Thomas J. Turbyville, Frederick, MD
- Dhirendra Simanshu, Frederick, MD
- Marco Biancucci, Chicago, IL
- Perry Kennedy, Tampa, FL
▲ MEET AND GREET • 4:00 p.m.–5:00 p.m.

AACR Publications Booth (2030), Exhibit Halls G-J
Meet the Editor-in-Chief of Cancer Research
(not eligible for CME credit)
George C. Prendergast, Wynnewood, PA

▲ CLINICAL TRIALS PLENARY SESSION 2 • 4:15 p.m.–6:00 p.m.

La Nouvelle Ballroom, Morial Convention Center
Precision Medicine Early Clinical Trials
Chairperson and discussants to be announced

CT005 Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors. Jayesh Desai, Melbourne, Australia

CT006 Crizotinib achieves objective responses and long-lasting disease control in patients (pts) with metastatic papillary renal cell carcinoma type 1 (PRCC1) with somatic MET mutations: EORTC phase II trial 90101 “CREATE.” Patrick Schoffski, Leuven, Belgium

CT007 Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements - Updated phase I results. Alexander Drilon, New York, NY

CT008 Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. David S. Hong, Houston, TX
CLINICAL TRIALS MINISYMPOSIUM • 4:15 p.m.-6:15 p.m.

Room 291, Morial Convention Center

Early Clinical Trials of Agents Targeting DNA Repair or the Epigenome

Chairperson to be announced

4:15 p.m.  CT010  Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations. Vasiliki Michalarea, London, United Kingdom

4:30 p.m.  CT011  Safety and efficacy results from a phase I dose-escalation trial of the PARP inhibitor talazoparib in combination with either temozolomide or irinotecan in patients with advanced malignancies. Zev A. Wainberg, Santa Monica, CA

4:45 p.m.  CT012  Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792). Geoffrey Shapiro, Boston, MA

5:00 p.m.  CT013  A phase Ib, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD1775 monotherapy in patients with advanced solid tumors: initial findings. David Spigel, Nashville, TN

5:15 p.m.  CT014  GS525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers. Peter J. O’Dwyer, Philadelphia, PA

5:30 p.m.  CT015  Results from a phase I/II study with the HDAC inhibitor entinostat in combination with high-dose interleukin-2 in renal cell carcinoma patients (CTEP#7870). Roberto Pili, Indianapolis, IN

5:45 p.m.  CT016  Abexinostat (ABX) as a means to reverse pazopanib (PAZ) resistance: a phase I study in advanced solid tumor malignancies. Pamela N. Munster, San Francisco, CA

6:00 p.m.  CT017  A phase I study of guadecitabine (GUA) combined with irinotecan (IRI) in previously treated metastatic colorectal cancer (mCRC) patients. Nilofer Azad, Baltimore, MD
DRUG DEVELOPMENT TRACK: SPECIAL SESSION
4:15 p.m.–6:15 p.m.

New Orleans Theater C, Morial Convention Center

New Drugs on the Horizon 2

Co-Chairpersons: Steven K. Davidsen, Libertyville, IL; Cynthia Seidel-Dugan, Belmont, MA

4:15 p.m. eFT508: An oral, potent and highly selective inhibitor of mitogen-activated protein kinase interacting kinase (MNK) 1 and 2, a novel approach for the treatment of cancer. Kevin R. Webster, San Diego, CA (not eligible for CME credit)


5:03 p.m. CD22 Targeted Thorium Conjugate (TTC): A first in class alpha-pharmaceutical. Alan S. Cuthbertson, Oslo, Norway

5:27 p.m. From Patient derived xenograft to patient: Development of SAR428926, a new maytansin-antibody drug conjugate. Veronique Blanc, Vitry-sur-Seine, France (not eligible for CME credit)

5:51 p.m. FPA144: A therapeutic monoclonal antibody with enhanced antibody-dependent cell killing for the treatment of fibroblast growth factor receptor 2b overexpressing cancers. Kristen L. Pierce, South San Francisco, CA (not eligible for CME credit)

LATE-BREAKING MINISYMPOSIUM • 4:15 p.m.–6:15 p.m.

Room 275, Morial Convention Center

Late-Breaking Minisymposium

Chairperson: Piro Lito, New York, NY

4:20 p.m. LB-068 Classification of cancer by synthesis of rare non-coding mutations within recurrent epigenetic and protein networks. Wei Zhang, La Jolla, CA

4:35 p.m. LB-069 ESR1 mutations in circulating tumour DNA predict outcome to endocrine treatment in patients with estrogen receptor positive advanced breast cancer: Analysis of 521 patients in the SoFEA and PALOMA3 trials. Ben O’Leary, London, United Kingdom

4:50 p.m. LB-070 Next generation sequencing of prostate cancer reveals germline and somatic alterations detected at diagnosis and at metastasis that may impact clinical decision making. Michael F. Walsh, New York, NY

5:05 p.m. LB-071 Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Piro Lito, New York, NY
Minisymposia: Abstract Presentations

The complete titles and text of minisymposium abstracts are available in the following formats:

- Online Itinerary Planner
- Annual Meeting App (for iOS and Android devices)
5:20 p.m.  LB-072  Impact of baseline serum cytokines on survival in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) or docetaxel (doc): Exploratory analyses from CheckMate 063 and CheckMate 017. Benedetto Farsaci, Princeton, NJ

5:35 p.m.  LB-073  Epigenome evolution in relapsed acute myeloid leukemia. Sheng Li, New York, NY

5:50 p.m.  LB-074  Regression of duodenal neoplasia in familial adenomatous polyposis patients using COX and EGFR inhibition: A randomized placebo-controlled trial. Deborah W. Neklason, Salt Lake City, UT

▲MINISYMPOSIA • 4:15 p.m.–6:15 p.m.

Room 243, Morial Convention Center
Bioinformatics and Systems Biology
Novel and Integrative Analyses of Cancer Genome Data

Co-Chairpersons: Trevor J. Pugh, Toronto, ON, Canada; Jinghui Zhang, Memphis, TN

4:15 p.m.  Introduction

4:20 p.m.  846  Improving T-cell receptor clonotyping of T-cell lymphomas using hybrid-Capture and next-generation sequencing. Etienne Mahe, Calgary, AB, Canada

4:35 p.m.  847  Molecular characterization of breast tumor T-cell infiltration in exome datasets. Olivier Harismendy, La Jolla, CA

4:50 p.m.  848  Proteogenomic analysis of alternative splicing: The search for novel biomarkers for colorectal cancer. Malgorzata A. Komor, Amsterdam, The Netherlands

5:05 p.m.  849  Improved geometric deconvolution of bulk tumor genomic data. Theodore Roman, Pittsburgh, PA

5:20 p.m.  850  Comprehensive genome and transcriptome structural analysis of a breast cancer cell line using single molecule sequencing. Maria Nattestad, Cold Spring Harbor, NY

5:35 p.m.  851  Analysis of cancer-initiating mosaic mutation in germline samples of pediatric cancer patients by next generation sequencing. Xiaotu Ma, Memphis, TN

5:50 p.m.  852  Modeling the emergence of resistance to chemotherapeutics with virtual tumor. Eric Fernandez, Oxford, United Kingdom (not eligible for CME credit)
Room 391, Morial Convention Center

Clinical Research

Biomarkers to Direct Cancer Therapy

Co-Chairpersons: Eliezer Van Allen, Boston, MA; Nicholas C. Turner, London, United Kingdom

4:15 p.m. Introduction

4:20 p.m. 853 Novel quantitative multiplexed PD-1/PD-L1 immunohistochemistry test provides superior prediction of treatment response in melanoma patients. Jennifer Bordeaux, Carlsbad, CA (not eligible for CME credit)

4:35 p.m. 854 Mutation load measured using a 315 gene panel predicts genome-wide mutation load. Artur Veloso, Cambridge, MA

4:50 p.m. 855 p53 isoform Δ133p53β triple negative breast cancer and increased relapse with neoadjuvant taxanes. Alastair M. Thompson, Houston, TX

5:05 p.m. 856 Number of ALK-amplified circulating tumor cells predicts progression-free survival in ALK-rearranged non-small cell lung cancer patients treated by crizotinib. Emma Pailler, Villejuif, France

5:20 p.m. 857 Diagnostic test system for sensitive, specific and reproducible detection of EML4-ALK RNA fusion transcripts in the blood of patients with NSCLC. Hestia Mellert, Boulder, CO (not eligible for CME credit)

5:35 p.m. 858 Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: Results from the I-SPY 2 TRIAL. Denise M. Wolf, San Francisco, CA

5:50 p.m. 859 Gene and pathway differences between MammaPrint High1/High2 risk classes: Results from the I-SPY 2 TRIAL in breast cancer. Denise M. Wolf, San Francisco, CA

Room 271, Morial Convention Center

Endocrinology

Molecular Pharmacology of Hormone-dependent Malignancies

Co-Chairpersons: Matthew J. Ellis, Houston, TX; Suzanne A.W. Fuqua, Houston, TX

4:15 p.m. Introduction

4:20 p.m. 860 ESR1 coregulator binding inhibitor (ECBI): a novel agent for treating hormone therapy-resistant breast cancer. Ratna K. Vadlamudi, San Antonio, TX

4:35 p.m. 861 Global transcription factor repression by the coactivator SRC-1 mediates disease progression in endocrine-resistant breast cancer. Damir Vareslija, Dublin, Ireland

4:50 p.m. 862 WNT4 mediates endocrine response and resistance in invasive lobular carcinoma cell lines and patient tumor explants. Matthew J. Sikora, Pittsburgh, PA
5:05 p.m.  **863**  Differential activity and SERD sensitivity of clinical ESR1 mutations.  
Weiyi Toy, New York, NY

5:20 p.m.  **864**  Androgen receptor stability in prostate cancer is regulated by the co-chaperone Bag-1L.  
Laura Cato, Boston, MA

5:35 p.m.  **865**  Isolation of WDR77-mediated interaction between androgen receptor and p53 uncovers novel treatment strategy for prostate cancer.  
Sangeeta Kumari, Cleveland, OH

5:50 p.m.  **866**  Delineation of novel CYP24A1 transcriptional regulators.  
Wei Luo, Buffalo, NY

Room 265, Morial Convention Center  
**Experimental and Molecular Therapeutics**  
**Antibody-targeted Therapy**

**Co-Chairpersons:** Peter D. Senter, Bothell, WA; Mark X. Sliwkowski, South San Francisco, CA

4:15 p.m.  Introduction

4:20 p.m.  **867**  ABT-165 is a first-in-class therapeutic Dual Variable Domain Immunoglobulin (DVD-IgTM) that targets DLL4 and VEGF for the treatment of cancer.  
Yingchun Li, North Chicago, IL

4:35 p.m.  **868**  Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NG-HER2 ADC) for treatment of solid tumors.  
Bitha Narayanan, Pearl River, NY

4:50 p.m.  **869**  Meditope enablement and structural analysis of anti-CD33 antibodies.  
Calin D. Dumitru, San Diego, CA

5:05 p.m.  **870**  Derivation and characterization of antibodies from immune checkpoint blockade treated cancer patients.  
Mark Branum, Seattle, WA

5:20 p.m.  **871**  Nanoliposomal targeting of ephrin receptor A2 (EphA2): Preclinical in vitro and in vivo rationale.  
Walid S. Kamoun, Cambridge, MA  
(not eligible for CME credit)

5:35 p.m.  **872**  In vivo activity of a novel CDH6 targeting antibody-drug conjugate, including population-scale ovarian PDX clinical trial.  
Carl U. Bialucha, Cambridge, MA

5:50 p.m.  **873**  A novel MET-EGFR bispecific antibody LY3164530 shows advantage over combining MET and EGFR antibodies in tumor inhibition and overcome resistance.  
Ling Liu, Indianapolis, IN
Room 293, Morial Convention Center
Experimental and Molecular Therapeutics
Approaches to Elucidating and Overcoming Drug Resistance

Co-Chairpersons: Ashani T. Weeraratna, Philadelphia, PA; Amaya Viros, Manchester, United Kingdom

4:15 p.m.  Introduction
4:20 p.m.  874 Circadian/melatonin disruption by dim light at night drives paclitaxel resistance in breast cancer via activation of stat3. Steven M. Hill, New Orleans, LA
4:35 p.m.  875 Acquisition of chemoresistance in tumor cells requires crosstalk between dying and remnant live tumor cells via HMGB1. Junmin Zhou, Tampa, FL
4:50 p.m.  876 Genome-scale genetic knockout screen identifies modifiers of EGFR dependence in non-small cell lung cancer cells. Jon DiMaina, Charleston, SC
5:05 p.m.  877 Evolution of resistance to EGFR inhibition from drug tolerant cancer cells. Aaron N. Hata, Boston, MA
5:20 p.m.  878 Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Mariangela Russo, Turin, Italy
5:35 p.m.  879 Single cell analysis resolves combinatory targeted therapy for arresting the BRAFi-induced cellular dedifferentiation of metastatic melanomas. Yapeng Su, Pasadena, CA
5:50 p.m.  880 Mapping the metastatic colorectal cancer phospho-proteome for predicting response to cetuximab. Robin Beekhof, Amsterdam, The Netherlands

Room 343, Morial Convention Center
Molecular and Cellular Biology/Genetics
Disordered Gene Regulation and Chromatin State in Malignant Transformation

Co-Chairpersons: Omar I. Abdel-Wahab, New York, NY; Charles Lin, Houston, TX

4:15 p.m.  Introduction
4:20 p.m.  881 Dissecting chromatin dynamics in malignant progression. Hanseul Yang, New York, NY
4:35 p.m.  882 TMPRSS2-ERG drives global mistargeting of mammalian SWI/SNF (BAF) complexes in prostate cancer. Gabriel J. Sandoval, Boston, MA
4:50 p.m.  883 NUP98-fusion proteins interact with the NSL/MLL1 complexes to drive leukemogenesis. Haiming Xu, New York, NY
5:05 p.m.  884 NSD3-short is an adaptor protein that couples BRD4 to the CHD8 chromatin remodeler. Chen Shen, Cold Spring Harbor, NY
5:20 p.m.  885  Epigenetic regulation of estrogen receptor transcription by the PI3K pathway in breast cancer.  Toska Eneda, New York, NY

5:35 p.m.  886  Notch signaling activates B-cell specific enhancers to drive oncogene targets in B-cell lymphoma.  Russell J. Ryan, Boston, MA

5:50 p.m.  887  N-Myc drives neuroendocrine prostate cancer.  David S. Rickman, New York, NY

Room 260, Morial Convention Center

Molecular and Cellular Biology/Genetics

Oncogene and Tumor Suppressor Function and Targeting

Chairperson:  Adolfo Ferrando, New York, NY; Michael M. Shen, New York, NY

4:15 p.m.  Introduction

4:20 p.m.  888  Inactivation of the DLC1 RhoGAP tumor suppressor by point mutation occurs commonly in human cancer and can result from Rho-dependent or Rho-independent mechanisms.  Douglas R. Lowy, Bethesda, MD

4:35 p.m.  889  Dissecting the role of MYC in BRCA1-associated breast cancer.  Chiara S. Brambillasca, Amsterdam, The Netherlands

4:50 p.m.  890  TGFβ upregulation mediates growth retardation in EGFR T790M mutant non-small cell lung cancer.  Pinar O. Eser, Boston, MA

5:05 p.m.  891  Dual defects of MDM2/MDMX-p53 pathways cause global metabolic disruption and enhance tumorigenesis.  Hua Lu, New Orleans, LA

5:20 p.m.  892  Functional characterization of EIF1AX mutations in thyroid cancer predicts for gain of function by increasing translational rate with concomitant derepression of upstream inputs from mTOR.  Gnana P. Krishnamoorthy, New York, NY

5:35 p.m.  893  Diffuse gastric adenocarcinoma often harbors KMT2C mutations resulting in malignant phenotypes and worse overall survival.  Changhwan Yoon, New York, NY

5:50 p.m.  894  Discovery of YAP-TEAD protein-protein interaction (PPI) inhibitors for cancer therapy.  Claudia Fromond, Daix, France
Prevention Research

Highlights in Cancer Prevention Advances

Co-Chairpersons: Avrum E. Spira, Boston, MA; Norman E. Sharpless, Chapel Hill, NC

4:15 p.m. Introduction

4:20 p.m. 895 Genomic characterization of premalignant lung squamous cell carcinoma lesions. Joshua D. Campbell, Cambridge, MA

4:35 p.m. 896 The airway field of injury reflects gene expression changes associated with the presence of lung squamous premalignant lesions. Sarah A. Mazzilli, Boston, MA

4:50 p.m. 897 Methionine restriction alters functional polarization of macrophages in a murine model of prostate cancer. Ashley Orillion, Indianapolis, IN

5:05 p.m. 898 Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. Joao Incio, Boston, MA

5:20 p.m. 899 Cancer protection associated with dietary methyl donor deficiency is characterized by persistent changes to epithelial proliferation and metabolism. Matthew P. Hanley, Farmington, CT

5:35 p.m. 900 In vivo modeling of NRAS-mutant melanoma reveals differential preventative efficacy amongst SPF30 sunscreens. Andrea M. Holderbaum, Columbus, OH

5:50 p.m. 901 Transgenerational inheritance of increased mammary cancer risk in the offspring of high fat diet fed dams: Changes in oxidative stress pathways. Nguyen M. Nguyen, Washington, DC

New Orleans Theater A, Morial Convention Center

Tumor Biology

Immunomodulation in Cancer

Chairperson: Samir N. Khleif, Augusta, GA; Angel Porgador, Beer-Shera, Israel

4:15 p.m. Introduction

4:20 p.m. 902 A small molecule glycomimetic antagonist of E-selectin and CXCR4 (GMI-1359) delays pancreatic tumor metastasis and significantly alters the pancreatic tumor microenvironment. Maria M. Steele, Omaha, NE

4:35 p.m. 903 IFN-γ induced PD-L1 on tumor and host cells co-operatively prevents tumor immune elimination after cancer immunoediting. Takuro Noguchi, St. Louis, MO

4:50 p.m. 904 Heterozygous ATG7 inhibition enhances endocrine therapy responsiveness through regulation of damage associated molecular patterns and priming the immune system in ER+ breast tumors. Katherine L. Cook, Winston-Salem, NC
5:05 p.m.  905  Pterostilbene (PTER) suppresses breast cancer brain metastasis by targeting a c-Met mediated inflammation network. Fei Xing, Winston-Salem, NC

5:20 p.m.  906  Exosomes from mutant TP53 cancer cells polarize tumor associated macrophages. Tomer Cooks, Bethesda, MD

5:35 p.m.  907  Brain microenvironment induced PTEN loss by microRNAs promotes brain metastasis. Lin Zhang, Houston, TX

5:50 p.m.  908  Immune regulation of tumor dormancy in syngeneic mouse model. Raziye Piranlioglu, Augusta, GA

Room 393, Morial Convention Center
Tumor Biology
The Relevance of Stemness Properties in Cancer

Co-Chairpersons: John E. Dick, Toronto, ON, Canada; Tannishtha Reya, La Jolla, CA

4:15 p.m.  Introduction

4:20 p.m.  909  How glioma stem cells maintain stemness outside their niche. Jian Hu, Houston, TX

4:35 p.m.  910  Genetic subclone heterogeneity of the human colon cancer initiating cell compartment. Klara M. Giessler, Heidelberg, Germany

4:50 p.m.  911  BRM loss promotes tumor progression through extracellular matrix remodeling and elevated mammary epithelial stem/progenitor activity. Jason J. Northey, San Francisco, CA

5:05 p.m.  912  Mist1+ secretory progenitor cells can give rise to cancer in the intestine and colon. Hayakawa Yoku, New York, NY

5:20 p.m.  913  Novel leukemia stem cell-targeted therapy for acute myeloid leukemia based on dual inhibition of EZH1/EZH2. Shuhei Fujita, Tokyo, Japan

5:35 p.m.  914  Sox10 regulates stem- and mesenchymal-like features in mammary cells. Christopher Dravis, La Jolla, CA

5:50 p.m.  915  RNA processing signatures of normal versus malignant progenitor cell aging predict leukemia stem cell sensitivity to RNA splicing modulation. Leslie A. Crews, La Jolla, CA
A CANCER DIALOGUE • 4:30 p.m.-6:00 p.m.

Maximizing Cancer Cures: How Do We Get There?

Panelists: Sandra J. Horning, San Francisco, CA
William G. Kaelin, Boston, MA
Richard Pazdur, Silver Spring, MD

Additional panelists to be announced.

NCI/NIH-SPONSORED SESSION • 5:30 p.m.-6:15 p.m.

The NCI PREVENT Cancer Preclinical Drug Development Program
(not eligible for CME credit)

Speaker: Robert H. Shoemaker, Bethesda, MD
TOWN MEETING • 6:00 p.m.–8:00 p.m.

Mardi Gras Ballroom D-E, New Orleans Marriott
Tumor Microenvironment Working Group (TME)
Town Hall Meeting and Reception
(not eligible for CME credit)

6:00 p.m.  Chairperson: Opening remarks. Morag Park, Montréal, QC, Canada
6:15 p.m.  Chairperson-elect: Remarks. Johanna A. Joyce, Lausanne, Switzerland
6:30 p.m.  Reciprocal interactions between the cancer cell and the tumor microenvironment during metastasis. Andrew J. Ewald, Baltimore, MD
6:50 p.m.  Heterogeneity of innate immune cell behavior and function in primary and metastatic tumors revealed by intravital imaging. Mikala Egeblad, Cold Spring Harbor, NY
7:10 p.m.  Heterotypic tumor-stroma cell-cell contacts: A new mechanism of crosstalk. Erik Sahai, London, United Kingdom
7:30 p.m.  Closing remarks. Johanna A. Joyce, Lausanne, Switzerland
New Orleans Theater Foyer, Morial Convention Center

Networking Hubs
(not eligible for CME credit)

Networking Hub: Epigenetics
Shelley L. Berger, Philadelphia, PA
Tomasz Cierpicki, Ann Arbor, MI
Nada Jabado, Montréal, QC, Canada
Cigall Kadoch, Boston, MA
Ross L. Levine, New York, NY
Ari M. Melnick, New York, NY
Udo Oppermann, Oxford, United Kingdom
Charles W.M. Roberts, Memphis, TN
Kimberly Stegmaier, Boston, MA

Networking Hub: Metabolism
Lewis C. Cantley, New York, NY
Ralph J. DeBerardinis, Dallas, TX
Robert N. Eisenman, Seattle, WA
Eyal Gottlieb, Glasgow, United Kingdom
Reuben J. Shaw, La Jolla, CA
Matthew G. Vander Heiden, Cambridge, MA
Katharine Yen, Cambridge, MA

Networking Hub: Genomics and Precision Medicine
Michael Berger, New York, NY
Malachi Griffith, St. Louis, MO
Mignon L. Loh, San Francisco, CA
Louis M. Staudt, Bethesda, MD

Networking Hub: Tumor Heterogeneity and Therapeutic Resistance
Alberto Bardelli, Candiolo, Italy
Caroline Dive, Manchester, United Kingdom
Jeffrey A. Engelman, Boston, MA
William C. Hahn, Boston, MA
Anthony G. Letai, Boston, MA
Dana Pe’er, New York, NY
Aviv Regev, Cambridge, MA
Charles Swanton, London, United Kingdom
TOWN MEETING • 6:30 p.m.–8:00 p.m.

Room 278, Morial Convention Center
Chemistry in Cancer Research Working Group (CICR)
Town Hall Meeting and Reception
(not eligible for CME credit)
6:30 p.m.  Opening remarks: CICR Chairperson. David E. Uehling, Toronto, ON, Canada
6:40 p.m.  Remarks: CICR Chairperson-elect. Steven K. Davidsen, Libertyville, IL
6:50 p.m.  Update from the CICR quarterly newsletter editor. Klaus Pors, Bradford, United Kingdom
7:00 p.m.  Discussion of member issues and closing remarks. Steven K. Davidsen, Libertyville, IL

TOWN MEETING • 6:30 p.m.–9:00 p.m.

Grand Salon B, Hilton New Orleans Riverside
AACR Pediatric Cancer Working Group Town Hall
Meeting and Networking Reception
(not eligible for CME credit)
Chairperson: Garrett M. Brodeur, Philadelphia, PA
Panel discussion: Issues surrounding pediatric cancer drug development and access
Panelists: Peter C. Adamson, Philadelphia, PA
          Samuel C. Blackman, Seattle, WA
          Nancy Goodman, Washington, DC
          Lee J. Helman, Bethesda, MD
          Donna Ludwinski, New York, NY
          Crystal L. Mackall, Palo Alto, CA
          Raphaël F. Rousseau, South San Francisco, CA